New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.
Start Your Search

Moderna’s mRNA Flu Vaccine Enters Trials

The same technology behind the COVID-19 vaccine looks to take on normal seasonal bugs next.

Moderna was a major player in the race to develop a vaccine for COVID-19. Now, according to a recent Engadget article, the company is using the same mRNA-based technology to combat the seasonal flu. The company announced last Wednesday that it has begun human trials as part of a Phase 1/2 clinical study.

The vaccine goes by the name mRNA-1010, and it’s designed to fight the four most common strains of the virus. These include A H1N1, H3N2, influenza B Yamagata, and influenza B Victoria, which account for 3-5 million severe flu cases each year and roughly 650,000 flu-related respiratory deaths.

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts